International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

A comparative analysis of UV-visible spectroscopic method vs HPLC method for determining content assay of ciprofloxacin 500 MG tablets

Author Affiliations

  • 1Department of Pharmacy, Hamdard Institute of Pharmaceutical Sciences, Islamabad, Pakistan
  • 2Akhtar Saeed College of Pharmaceutical Sciences, AMDC, Lahore, Pakistan

Res. J. of Pharmaceutical Sci., Volume 7, Issue (1), Pages 1-6, June,30 (2018)


Ciprofloxacin tablets are usually prescribed in GIT infections particularly in typhoid. In Pakistan there are several brands of ciprofloxacin available with different trade names in local market. The standard method of determining the amount of active ingredient present in tablets described by US Pharmacopeia is HPLC method. This study was conducted to compare the results of analysis of UV-visible spectroscopic method and HPLC method to determine the amount of ciprofloxacin (active) present in different brands. Content assay was performed by these two methods. Other tests like weight variation, hardness, disintegration and dissolution test were performed on all brands under study. For this study eight brands of ciprofloxacin were purchased from local market of Islamabad and evaluated on the basis of above mentioned tests according to compendial methods. Results showed that all brands complied with USP specifications for all parameters. UV-visible spectroscopic method showed reliable and comparable results to that of HPLC method so this can provide a reliable method for assay of the drug as that of compendial method HPLC.


  1. Guimarães D.O., Momesso L.D.S. and Pupo M.T. (2010)., Antibiotics: therapeutic importance and perspectives for the discovery and development of new agents., Química Nova, 33(3), 667-679.
  2. Mitscher L.A. (2005)., Bacterial topoisomerase inhibitors: Quinolone and pyridone antibacterial agents., Chem. Rev., 105, 559-592.
  3. Andriole V.T. (2005)., The quinolones: Past, present, and future., Clin. Infect, 41(2), 113-119.
  4. Bertino J. (2000)., The safety profile of the fluoroquinolones., Clinical therapeutics, 22(7), 798-817.
  5. Nasimullah M., Rahman I. and Akhtar G. (2012)., Comparative analysis of Ciprofloxacin in different pharmaceutical products by high performance liquid chromatography., Sci., Tech. and Dev., 31(1), 69-73.
  6. Scherer R., Pereira J, Firme J. and Lemos M. (2014)., Determination of Ciprofloxacin in Pharmaceutical Formulations using HPLC Method with UV Detection., Indian J Pharm Sci., 76(6), 541-544.
  7. Louie Thomas J. (1994)., Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens., Can Med Assoc J., 150(5), 669-676.
  8. Fratini L. and Schapoval E.E. (1996)., Ciprofloxacin determination by visible light spectrophotometry using iron (III) nitrate., Int J Pharm, 127(2), 279-282.
  9. Belal F., Al-Majed A.A. and Al-Obaid A.M. (1999)., Methods of analysis of 4-quinolone antibacterials., Talanta., 50(4), 765-786.
  10. Husain S., Khalid S., Nagaraju V. and Rao R.N. (1995)., High-performance liquid chromatographic separation and determination of small amounts of process impurities of ciprofloxacin in bulk drugs formulations., J Chromatogr., 705, 380-384.
  11. Torniainen K., Tammilehto S. and Ulvi V. (1996)., The effect of pH, buffer type and drug concentration on the photo degradation of ciprofloxacin., Int J Pharm., 132, 53-61.
  12. Zupan M., Turel I., Bukovec P., White Andrew J.P. and William David J. (2001)., Synthesis and Characterization of Two Novel Zinc (II) Complexes with Ciprofloxacin., Croatica Chemica Acta., 74(1), 61-74.
  13. The United States pharmacopoeia (2013), 36, National Formulary 31., undefined, undefined
  14. Ngwuluka N.C., Lawal K., Olorunfemi P.O. and Ochekpe N.A. (2009)., Post-market in vitro bioequivalence study of six brands of ciprofloxacin tablets/caplets, Jos, Nigeria., Scientific research and essay, 4(4), 298-305.